Article
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
BMC cancer - 15 Dec 2022
Fukui Tomoya, Sasaki Jiichiro, Igawa Satoshi, Kada Akiko, Saito Toshiki I, Kogure Yoshihito, Okamoto Hiroaki, Naoki Katsuhiko
Abstract excerpt
BACKGROUND: Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, can be used in patients with poor performance status owing to their high efficacy and safety. The third-generation EGFR-tyrosine kinase inhibitor osimertinib has demonstrated effectiveness...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.